Key facts
- It has raised $570K; the latest was PE Growth/Expansion ($570K) in Mar 2025.
- Notable investors include BroadOak Capital Partners, JLL Partners, Water Street Healthcare Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Solvias
- ·The full record, as it builds
Funding rounds
No funding rounds for Solvias are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Solvias
Operator of a contract research and contract manufacturing company intended to serve the pharmaceutical, biotechnology, medical devices, and cosmetics industries. The company offers a variety of products, including chiral phosphine ligands, catalysts, and process sampling equipment, along with CMC analytical services, enabling clients to overcome complex challenges and accelerate their path to commercialization.
- Sector
- Healthcare
- HQ
- Kaiseraugst, Switzerland
- Founded
- 1999
- Employees
- 800
- Website
- solvias.com/
- Ownership
- Privately Held (backing)
Solvias doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Solvias shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Solvias in its N-PORT filings yet. We sweep new filings monthly.